Your browser doesn't support javascript.
Comparison of one single-antigen assay and three multi-antigen SARS-CoV-2 IgG assays in Nigeria.
Iriemenam, Nnaemeka C; Ige, Fehintola A; Greby, Stacie M; Okunoye, Olumide O; Uwandu, Mabel; Aniedobe, Maureen; Nwaiwu, Stephnie O; Mba, Nwando; Okoli, Mary; William, Nwachukwu E; Ehoche, Akipu; Mpamugo, Augustine; Mitchell, Andrew; Stafford, Kristen A; Thomas, Andrew N; Olaleye, Temitope; Akinmulero, Oluwaseun O; Agala, Ndidi P; Abubakar, Ado G; Owens, Ajile; Gwyn, Sarah E; Rogier, Eric; Udhayakumar, Venkatachalam; Steinhardt, Laura C; Martin, Diana L; Okoye, McPaul I; Audu, Rosemary.
  • Iriemenam NC; Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Abuja, Nigeria.
  • Ige FA; Center for Human Virology and Genomics, Microbiology Department, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria.
  • Greby SM; Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Abuja, Nigeria.
  • Okunoye OO; Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Abuja, Nigeria.
  • Uwandu M; Center for Human Virology and Genomics, Microbiology Department, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria.
  • Aniedobe M; Center for Human Virology and Genomics, Microbiology Department, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria.
  • Nwaiwu SO; Center for Human Virology and Genomics, Microbiology Department, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria.
  • Mba N; Nigeria Centre for Disease Control (NCDC), Gaduwa, FCT, Nigeria.
  • Okoli M; Nigeria Centre for Disease Control (NCDC), Gaduwa, FCT, Nigeria.
  • William NE; Nigeria Centre for Disease Control (NCDC), Gaduwa, FCT, Nigeria.
  • Ehoche A; University of Maryland Center for International Health, Education, and Biosecurity (CIHEB), Maryland Global Initiatives Corporation (MGIC), FCT, Nigeria.
  • Mpamugo A; University of Maryland Center for International Health, Education, and Biosecurity (CIHEB), Maryland Global Initiatives Corporation (MGIC), FCT, Nigeria.
  • Mitchell A; Center for International Health, Education, and Biosecurity, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, USA.
  • Stafford KA; Center for International Health, Education, and Biosecurity, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, USA.
  • Thomas AN; International Research Center of Excellence, Institute of Human Virology, Abuja, Nigeria.
  • Olaleye T; International Research Center of Excellence, Institute of Human Virology, Abuja, Nigeria.
  • Akinmulero OO; International Research Center of Excellence, Institute of Human Virology, Abuja, Nigeria.
  • Agala NP; International Research Center of Excellence, Institute of Human Virology, Abuja, Nigeria.
  • Abubakar AG; International Research Center of Excellence, Institute of Human Virology, Abuja, Nigeria.
  • Owens A; Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Gwyn SE; Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Rogier E; Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Udhayakumar V; Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Steinhardt LC; Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Martin DL; Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Okoye MI; Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Abuja, Nigeria.
  • Audu R; Center for Human Virology and Genomics, Microbiology Department, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria.
J Clin Virol Plus ; 3(1): 100139, 2023 Feb.
Article in English | MEDLINE | ID: covidwho-2180299
ABSTRACT

Objectives:

Determining an accurate estimate of SARS-CoV-2 seroprevalence has been challenging in African countries where malaria and other pathogens are endemic. We compared the performance of one single-antigen assay and three multi-antigen SARS-CoV-2 IgG assays in a Nigerian population endemic for malaria.

Methods:

De-identified plasma specimens from SARS-CoV-2 RT-PCR positive, dried blood spot (DBS) SARS-CoV-2 RT-PCR positive, and pre-pandemic negatives were used to evaluate the performance of the four SARS-CoV-2 assays (Tetracore, SARS2MBA, RightSign, xMAP).

Results:

Results showed higher sensitivity with the multi-antigen (81% (Tetracore), 96% (SARS2MBA), 85% (xMAP)) versus the single-antigen (RightSign (64%)) SARS-CoV-2 assay. The overall specificities were 98% (Tetracore), 100% (SARS2MBA and RightSign), and 99% (xMAP). When stratified based on <15 days to ≥15 days post-RT-PCR confirmation, the sensitivities increased from 75% to 88.2% for Tetracore; from 93% to 100% for the SARS2MBA; from 58% to 73% for RightSign; and from 83% to 88% for xMAP. With DBS, there was no positive increase after 15-28 days for the three assays (Tetracore, SARS2MBA, and xMAP).

Conclusion:

Multi-antigen assays performed well in Nigeria, even with samples with known malaria reactivity, and might provide more accurate measures of COVID-19 seroprevalence and vaccine efficacy.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study Topics: Vaccines Language: English Journal: J Clin Virol Plus Year: 2023 Document Type: Article Affiliation country: J.jcvp.2023.100139

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study Topics: Vaccines Language: English Journal: J Clin Virol Plus Year: 2023 Document Type: Article Affiliation country: J.jcvp.2023.100139